articleClinical Cancer ResearchSep 30, 2008Closed access

Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

JSJohann S. de BonoHIHoward I. ScherBMBruce MontgomeryCPChristopher ParkerMCMichael Craig Miller

Royal Marsden Hospital · Memorial Sloan Kettering Cancer Center · +4 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Results

Two hundred thirty-one of 276 enrolled patients (84%) were evaluable. Patients with Unfavorable pretreatment CTC (57%) had shorter OS (median OS, 11.5 versus 21.7 months; Cox hazard ratio, 3.3; P 26 to 9.3 months).

Conclusions

CTC are the most accurate and independent predictor of OS in CRPC. These data led to Food and Drug Administration clearance of this assay for the evaluation of CRPC.

Citation impact

2,180
total citations
FWCI
37.12
Percentile
100%
References
23
Citations per year

Authors

10

Topics & keywords

Topics
Keywords
  • Medicine
  • Prostate cancer
  • Circulating tumor cell
  • Hazard ratio
  • Urology
  • Proportional hazards model
  • Internal medicine
  • Oncology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.